On Monday shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) closed at $11.87. Company’s sales growth for last 5 years was 117.70% and EPS growth for next 5 years is recorded as 5.60%. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that it will present preclinical and clinical data showcasing its deep oncology pipeline at the 2015 American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.
Visa Inc. (NYSE:V) in last trading activity increased 0.18% to close at $65.66. Company weekly performance is -2.12% while its quarterly performance stands at -1.31%. Visa Inc. (NYSE:V) is -5.74% away from its 52 week high. On 20 March, Visa Inc. (NYSE:V) said that, it plans to hire 500 engineers in Austin by the end of the year, according to company CMO Antonio Lucio.
On Monday shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) closed at $14.12. Company’s EPS growth for next 5 years is recorded as 40.00%. On 24 March, Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) announced operational, clinical and financial results for the year ended December 31, 2014. Dipexium ended the year on December 31, 2014, with cash totaling $27.0 million compared to $3.9 million for the year ending December 31, 2013. The increase was primarily attributable to the net proceeds of $34.5 million from the Company’s initial public offering.
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) in last trading activity moved down -2.31% to close at $0.50. Company weekly performance is -10.70% while its quarterly performance stands at -25.36%. ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) is -65.51% away from its 52 week high. On 19 March, ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) said that, PharmaCell B.V. finalized an agreement with ImmunoCellular Therapeutics Ltd. to support its pivotal phase III clinical trial in Europe with ICT-107. ICT 107 is a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the commonest and deadliest forms of brain cancer.